Added to YB: 2026-10-08
Pitch date: 2026-10-04
CATX [bullish]
Perspective Therapeutics, Inc.
-17.45%
current return
Author Info
No bio for this author
Company Info
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
Market Cap
$293.4M
Pitch Price
$2.75
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.50
P/E
-2.05
EV/Sales
147.82
Sector
Biotechnology
Category
special_situation
Free under $10 Ticker Biotech Quarter Review Tier 1 basket — strategic biotech and specialty pharma - Perspective Therapeutics, Inc.
CATX (quick overview): Perspective Therapeutics is a lead-212 radiopharmaceutical thesis whose strategic value rests on scarce alpha-emitter supply, radiochemistry capabilities, manufacturing know-how and clinically credible programs as larger oncology companies seek radiopharma capacity. The buyer case remains conditional: Perspective must demonstrate reliable supply, scalable manufacturing, and clinically useful efficacy and safety before it can fit into a larger nuclear-medicine or lutetium-based therapy franchise.
Read full article (1 min)